Investigators enrolled 98 patients to receive preoperative treatment with intravenous panitumumab plus concurrent radiotherapy.
Get the latest treatment options for rectal cancer, including concurrent chemotherapy and radiotherapy and levoleucovorin plus 5-FU.
Incomplete neoadjuvant radiotherapy is associated with worse overall survival in patients with locally advanced rectal cancer.
Compared with adults born in around 1950, those born around 1990 are at a 2-fold higher risk for colon cancers and a 4-fold higher risk for rectal cancers.
Among patients with rectal cancer, delaying surgery following short-course radiotherapy yields similar outcomes.
Radiation oncologists in the US are less likely to offer neoadjuvant short-course radiotherapy over long-course chemoradiotherapy.
Neoadjuvant chemotherapy (NCRT) is superior to neoadjuvant multi-agent chemotherapy (NMAC) for the treatment of stage II or III rectal adenocarcinoma.
Adjuvant chemotherapy is beneficial for patients with locally-advanced, postoperative rectal cancer.
Oxaliplatin-based preoperative chemoradiotherapy may yield more pathological complete responses (pCR) for locally-advanced rectal cancer.
Some patients with rectal cancer who experience complete clinical response after neoadjuvant therapy may safely avoid total mesorectal excision.
Metastatic colorectal cancer with the primary tumor located on the left side of the colon is associated with longer survival.
Single nucleotide polymorphism (SNP) IL17F-rs9463772 represents a prognostic marker of long-term survival in locally advanced rectal cancer.
Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.
Long-course oxaliplatin-based preoperative chemoradiation was similarly efficacious in patients with cT4 or fixed cT3 rectal cancer
Best length of time to wait to perform surgery for rectal cancer after chemotherapy and radiation treatment.
A substantial proportion of patients with rectal cancer managed by the watch-and-wait approach avoided a major operation.
Capecitabine should be considered a standard of care in the pre-operative rectal cancer setting.
Neoadjuvant chemoradiotherapy followed by local excision may be an organ-preserving alternative in certain patients with clinical T2N0 rectal cancer.
Two studies found that laparoscopic surgery for rectal cancer found that it was potentially inferior to open-surgery.
Aspirin might have anticancer activity against rectal cancer during preoperative chemoradiation.
Older patients seem to face similar outcomes as younger patients when treated with neoadjuvant chemoradiation for rectal cancer.
Standard combined modality treatment for locally advanced rectal cancer had less disease-free survival than a new CRO/ARO/AIO-04 regimen.
Cumulative exposure to statins after a diagnosis of colorectal cancer was associated with lower overall mortality.
Single nucleotide polymorphism in the let-7 complementary site 6 of KRAS mRNA may be a response biomarker in colorectal cancer.
Investigators recommend prioritized screening in certain pockets of the U.S. that are statistically identified as colorectal cancer (CRC) death hotspots.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
High-dose chemoradiotherapy and watchful waiting might be safe alternative to abdominoperineal resection for treatment of rectal cancer.
mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.
A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy